Applied Biosystems announces the global option of the 3500 Series Genetic Analyzer Applied Biosystems, part of Lifestyle Technologies Corporation , today announced the global commercial availability of a new capillary electrophoresis sequencing system. The 3500 Series Genetic Analyzer is for research use only not designed for diagnostic or therapeutic use prescription medication read more . Since May 2009, a lot more than 10 analysis institutions have already been participating in an early evaluation of the technology with main interest in learning the most more popular human genetic disorders, such as for example those caused by missing or extra chromosomes, as well as a broad spectral range of other diseases.
Related StoriesTIS physicians chosen as recipients of D Magazine 2015 Greatest Doctors in DallasResearchers examine how small wireless sensors built-into orthopedic implants might help detect SSIBiodegradable polymer could help heal the bones of patients with orthopedic injuriesApixaban is usually a novel, oral, extremely selective Element Xa inhibitor, a new class of agents becoming studied for the potential to prevent and treat blood clots in the veins and arteries.. Application for regulatory authorization of apixaban in Europe to be submitted Bristol-Myers Squibb Firm and Pfizer today announced that the companies are planning to fill out an application for regulatory authorization of apixaban in European countries for preventing venous thromboembolism after orthopedic medical procedures in the first fifty % of 2010.